{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"}],"units":"Participants"}],"description":"To determine safety of amivantamab in patients with recurrent and metastatic adenoid cystic carcinoma as measured by CTCAE v5. Any subject that had at least one adverse event will be counted.","groups":[{"description":"Amivantamab weekly for the first cycle and biweekly thereafter.\n\nAmivantamab: Patients will receive amivantamab at 1050mg weekly for the first cycle and biweekly thereafter (1400mg for patients ≥80kg).","id":"OG000","title":"Amivantamab"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Any subject that had at least one adverse event will be counted.","reportingStatus":"POSTED","timeFrame":"Up to 16 months regardless of attribution should be collected continuously during the treatment period and for a minimum of 30 days following the last dose of study treatment.","title":"Number of Participants With Adverse Events","type":"SECONDARY","unitOfMeasure":"Participants"}